A randomized, double-blind trial comparing the effects of amlodipine besylate/benazepril HCl vs amlodipine on endothelial function and blood pressure.

Emile R. Mohler, David Herrington, Pamela Ouyang, Charles Mangano, Susan Ritter, Pamela Davis, Das Purkayastha, Marjorie Gatlin, Robert A. Vogel

Research output: Contribution to journalArticle

Abstract

Evidence suggests that renin-angiotensin-aldosterone system inhibition ameliorates endothelial dysfunction. The authors examined the effect of amlodipine besylate/benazepril HCl combination treatment compared with amlodipine besylate monotherapy in modulating endothelial dysfunction. This multicenter, double-blind, 12-week study randomized 70 hypertensive subjects with at least one other endothelial dysfunction risk factor to amlodipine besylate/benazepril HCl (5/20 mg/d force-titrated to 5/40 mg/d) or amlodipine besylate monotherapy (5 mg/d force-titrated to 10 mg/d). Both the combination and monotherapy produced significant median increases from baseline in percentage flow-mediated vasodilation (2.0% and 1.2%, respectively) and percentage change in percent flow-mediated vasodilation (25% and 16%, respectively). These improvements were numerically larger with combination treatment, but between-group differences did not achieve statistical significance. Reductions in systolic and diastolic blood pressure were significantly greater (P=.0452/P=.0297) with combination treatment (-18.6/-12.3 mm Hg) than with monotherapy (-14.8/-9.1 mm Hg). A highly positive correlation between change in systolic blood pressure and change in percent of flow-mediated vasodilation was demonstrated only for combination treatment.

Original languageEnglish (US)
Pages (from-to)692-698
Number of pages7
JournalJournal of clinical hypertension (Greenwich, Conn.)
Volume8
Issue number10
StatePublished - Oct 2006
Externally publishedYes

Fingerprint

Amlodipine
Vasodilation
Blood Pressure
Renin-Angiotensin System
benazepril

ASJC Scopus subject areas

  • Internal Medicine

Cite this

A randomized, double-blind trial comparing the effects of amlodipine besylate/benazepril HCl vs amlodipine on endothelial function and blood pressure. / Mohler, Emile R.; Herrington, David; Ouyang, Pamela; Mangano, Charles; Ritter, Susan; Davis, Pamela; Purkayastha, Das; Gatlin, Marjorie; Vogel, Robert A.

In: Journal of clinical hypertension (Greenwich, Conn.), Vol. 8, No. 10, 10.2006, p. 692-698.

Research output: Contribution to journalArticle

Mohler, Emile R. ; Herrington, David ; Ouyang, Pamela ; Mangano, Charles ; Ritter, Susan ; Davis, Pamela ; Purkayastha, Das ; Gatlin, Marjorie ; Vogel, Robert A. / A randomized, double-blind trial comparing the effects of amlodipine besylate/benazepril HCl vs amlodipine on endothelial function and blood pressure. In: Journal of clinical hypertension (Greenwich, Conn.). 2006 ; Vol. 8, No. 10. pp. 692-698.
@article{048d5ea23fa94cf3b1e078e5533b58b7,
title = "A randomized, double-blind trial comparing the effects of amlodipine besylate/benazepril HCl vs amlodipine on endothelial function and blood pressure.",
abstract = "Evidence suggests that renin-angiotensin-aldosterone system inhibition ameliorates endothelial dysfunction. The authors examined the effect of amlodipine besylate/benazepril HCl combination treatment compared with amlodipine besylate monotherapy in modulating endothelial dysfunction. This multicenter, double-blind, 12-week study randomized 70 hypertensive subjects with at least one other endothelial dysfunction risk factor to amlodipine besylate/benazepril HCl (5/20 mg/d force-titrated to 5/40 mg/d) or amlodipine besylate monotherapy (5 mg/d force-titrated to 10 mg/d). Both the combination and monotherapy produced significant median increases from baseline in percentage flow-mediated vasodilation (2.0{\%} and 1.2{\%}, respectively) and percentage change in percent flow-mediated vasodilation (25{\%} and 16{\%}, respectively). These improvements were numerically larger with combination treatment, but between-group differences did not achieve statistical significance. Reductions in systolic and diastolic blood pressure were significantly greater (P=.0452/P=.0297) with combination treatment (-18.6/-12.3 mm Hg) than with monotherapy (-14.8/-9.1 mm Hg). A highly positive correlation between change in systolic blood pressure and change in percent of flow-mediated vasodilation was demonstrated only for combination treatment.",
author = "Mohler, {Emile R.} and David Herrington and Pamela Ouyang and Charles Mangano and Susan Ritter and Pamela Davis and Das Purkayastha and Marjorie Gatlin and Vogel, {Robert A.}",
year = "2006",
month = "10",
language = "English (US)",
volume = "8",
pages = "692--698",
journal = "Journal of clinical hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - A randomized, double-blind trial comparing the effects of amlodipine besylate/benazepril HCl vs amlodipine on endothelial function and blood pressure.

AU - Mohler, Emile R.

AU - Herrington, David

AU - Ouyang, Pamela

AU - Mangano, Charles

AU - Ritter, Susan

AU - Davis, Pamela

AU - Purkayastha, Das

AU - Gatlin, Marjorie

AU - Vogel, Robert A.

PY - 2006/10

Y1 - 2006/10

N2 - Evidence suggests that renin-angiotensin-aldosterone system inhibition ameliorates endothelial dysfunction. The authors examined the effect of amlodipine besylate/benazepril HCl combination treatment compared with amlodipine besylate monotherapy in modulating endothelial dysfunction. This multicenter, double-blind, 12-week study randomized 70 hypertensive subjects with at least one other endothelial dysfunction risk factor to amlodipine besylate/benazepril HCl (5/20 mg/d force-titrated to 5/40 mg/d) or amlodipine besylate monotherapy (5 mg/d force-titrated to 10 mg/d). Both the combination and monotherapy produced significant median increases from baseline in percentage flow-mediated vasodilation (2.0% and 1.2%, respectively) and percentage change in percent flow-mediated vasodilation (25% and 16%, respectively). These improvements were numerically larger with combination treatment, but between-group differences did not achieve statistical significance. Reductions in systolic and diastolic blood pressure were significantly greater (P=.0452/P=.0297) with combination treatment (-18.6/-12.3 mm Hg) than with monotherapy (-14.8/-9.1 mm Hg). A highly positive correlation between change in systolic blood pressure and change in percent of flow-mediated vasodilation was demonstrated only for combination treatment.

AB - Evidence suggests that renin-angiotensin-aldosterone system inhibition ameliorates endothelial dysfunction. The authors examined the effect of amlodipine besylate/benazepril HCl combination treatment compared with amlodipine besylate monotherapy in modulating endothelial dysfunction. This multicenter, double-blind, 12-week study randomized 70 hypertensive subjects with at least one other endothelial dysfunction risk factor to amlodipine besylate/benazepril HCl (5/20 mg/d force-titrated to 5/40 mg/d) or amlodipine besylate monotherapy (5 mg/d force-titrated to 10 mg/d). Both the combination and monotherapy produced significant median increases from baseline in percentage flow-mediated vasodilation (2.0% and 1.2%, respectively) and percentage change in percent flow-mediated vasodilation (25% and 16%, respectively). These improvements were numerically larger with combination treatment, but between-group differences did not achieve statistical significance. Reductions in systolic and diastolic blood pressure were significantly greater (P=.0452/P=.0297) with combination treatment (-18.6/-12.3 mm Hg) than with monotherapy (-14.8/-9.1 mm Hg). A highly positive correlation between change in systolic blood pressure and change in percent of flow-mediated vasodilation was demonstrated only for combination treatment.

UR - http://www.scopus.com/inward/record.url?scp=34548814852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548814852&partnerID=8YFLogxK

M3 - Article

C2 - 17028482

AN - SCOPUS:34548814852

VL - 8

SP - 692

EP - 698

JO - Journal of clinical hypertension

JF - Journal of clinical hypertension

SN - 0895-7061

IS - 10

ER -